SS
IMRX icon

SBI Securities’s Immuneering IMRX Stock Holding History

SBI Securities’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-74
Closed -$249 – 4250
2025
Q2 		$249 Hold
74
– – ﹤0.01% 3243
2025
Q1 		$112 Hold
74
– – ﹤0.01% 3407
2024
Q4 		$163 Buy
+74
New +$153 ﹤0.01% 3317

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SBI Securities's IMRX Position: Q3 2025 in Review

SBI Securities sold out of Immuneering (IMRX) in Q3 2025, closing a stake of 74 shares — an estimated $249 sold.

SBI Securities first reported a position in IMRX in Q4 2024 and held it in 3 quarters. The position peaked at $249 in Q2 2025. 68 funds tracked by Wall St. Rank hold IMRX as of Q3 2025.

  • SBI Securities reported no remaining Immuneering position as of Q3 2025 after selling out during the quarter.
  • SBI Securities sold 74 Immuneering shares in Q3 2025, an estimated $249.
  • SBI Securities first reported a position in Immuneering in Q4 2024 and held it in 3 quarters.
  • SBI Securities's Immuneering position peaked at $249 in Q2 2025.
  • 68 funds tracked by Wall St. Rank held Immuneering as of Q3 2025.

Based on SBI Securities's 13F filing for Q3 2025, filed 5 Nov 2025.